Nimotuzumab is a humanized monoclonal antibody (mAb) and recombinant biological active pharmaceutical ingredient directed against the epidermal growth factor receptor (EGFR/HER1). It belongs to the IgG1 class of therapeutic antibodies and has antineoplastic activity.
Nimotuzumab binds to EGFR and interferes with EGFR-mediated signaling pathways involved in cell proliferation and survival. WHO describes Nimotuzumab as an immunoglobulin G1 anti-human epidermal growth factor receptor antibody derived from the humanized mouse monoclonal antibody hR3.
Nimotuzumab is a specialized oncology biologic API used in pharmaceutical development, monoclonal-antibody research and the manufacture of therapeutic biological products.
Unlike conventional small-molecule APIs, Nimotuzumab is a complex protein therapeutic. Its quality is therefore evaluated using biological and biophysical attributes such as identity, purity, molecular size distribution, charge variants, protein concentration and biological potency, rather than conventional tests such as melting point or residue on ignition. Regulatory science for monoclonal antibodies supports this type of specification framework.
CAS Number: 828933-51-3
Molecular Formula: C₆₅₆₆H₁₀₀₈₂N₁₇₄₆O₂₀₅₆S₄₀
Approximate Molecular Weight: 147.58 kDa
Molecule Type: Humanized Monoclonal Antibody
Immunoglobulin Class: IgG1
Target: Epidermal Growth Factor Receptor (EGFR/HER1)
Drug Class: Anti-EGFR Monoclonal Antibody
Therapeutic Class: Antineoplastic / Targeted Biological Therapy
Therapeutic Area: Oncology
Origin: Humanized recombinant monoclonal antibody
WHO's INN documentation gives the molecular formula and CAS number for Nimotuzumab and describes it as a humanized mouse monoclonal hR3-derived IgG1 antibody targeting the human epidermal growth factor receptor.
Nimotuzumab binds specifically to EGFR, a transmembrane receptor involved in cellular proliferation, differentiation and survival.
Its activity includes:
Nimotuzumab is therefore relevant to targeted cancer therapy and EGFR-directed drug development.
Nimotuzumab API is relevant to:
Nimotuzumab has been investigated and used in EGFR-targeted treatment strategies for several cancers, including head and neck cancers and glioma, depending on the regulatory jurisdiction and approved indication.
Its therapeutic role is based on targeting EGFR-mediated signaling pathways involved in tumor growth.
EGFR, also known as HER1/ErbB1, is a receptor tyrosine kinase that participates in signaling pathways controlling cell proliferation and survival.
Nimotuzumab is designed to recognize EGFR and interfere with receptor-mediated signaling, making it relevant to targeted oncology and anti-EGFR therapeutic research.
Nimotuzumab is a large protein molecule rather than a conventional crystalline small molecule. Its reported molecular size is approximately 147.58 kDa. Technical reference material identifies it as a human IgG1 monoclonal antibody.
For this reason, properties such as melting point, residue on ignition and specific rotation are not appropriate primary API quality attributes for the CMS.
Published Nimotuzumab analytical work has used formulations around pH 6.5–7.5, while research-grade Nimotuzumab preparations have also been reported at other formulation pH values depending on the buffer system.
Therefore, the pH of a commercial Nimotuzumab drug substance or drug product should be taken from its validated formulation/API specification, rather than presenting a research formulation value as a universal API limit.
A controlled recombinant Nimotuzumab manufacturing process may involve:
Nimotuzumab quality assessment may include:
These are representative biologic quality attributes; exact acceptance limits must be established in the product-specific validated specification.
Nimotuzumab is a protein therapeutic and should be stored according to its validated stability program and approved product specification.
Research-grade Nimotuzumab materials have been stored frozen, including −20°C, while therapeutic formulations require their own approved cold-chain conditions.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| pH (1% Solution) | 6.5–7.5 |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 5.0% |